Lung Diseases Cies Search Engine [selected websites]


Blog Archive

Sep 25, 2008

Forest Laboratories and Almirall : Phase III Clinical Studies of Aclidinium Bromide Show Statistical Significance vs. Placebo in Patients With COPD

Sept. 3, 2008 - Forest Laboratories, Inc. (NYSE: FRX) and Laboratorios Almirall, S.A. announced results from two global Phase III studies of aclidinium bromide, a novel long-acting inhaled anticholinergic for the treatment of patients with chronic obstructive pulmonary disease (COPD).

In both the ACCLAIM/COPD I&II (AClidinium CLinical Trial Assessing Efficacy and Safety In Moderate to Severe COPD Patients) studies, once-daily aclidinium bromide showed a statistically significant difference vs. placebo in the primary endpoint trough FEV1, a measure of pulmonary function that is decreased in moderate to severe COPD patients... Forest Laboratories' Press Release -